Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5656650	ABBVIE	Angiotensin II receptor blocking compositions	Aug, 2014 (9 years ago)

Teveten is owned by Abbvie.

Teveten contains Eprosartan Mesylate.

Teveten has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Teveten are:

Teveten was authorised for market use on 22 December, 1997.

Teveten is available in tablet;oral dosage forms.

Teveten can be used as treatment of hypertension.

The generics of Teveten are possible to be released after 12 August, 2014.

Market Authorisation Date: 22 December, 1997

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 300MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
EQ 400MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
EQ 600MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued

Teveten patents expiration